Behavioral activating effects
of adrafinil in aged canines

Siwak CT, Gruet P, Woehrle F, Schneider M,
Muggenburg BA, Murphey HL, Callahan H, Milgram NW
Division of Life Sciences,
University of Toronto at Scarborough,
1265 Military Trail,
Ontario, M1C 1A4,
Scarborough, Canada.
Pharmacol Biochem Behav 2000 Jun; 66(2):293-300


Adrafinil, a vigilance enhancing pharmaceutical, was administered to aged dogs for 14 consecutive days at doses of 10, 20, 30, or 40 mg/kg using a crossover design. The effects on spontaneous behavior in a 10-min canine open-field test were systematically recorded every fourth day, starting with day 1 of treatment. The open field tests were given 2 or 10 h following oral administration of capsules containing either adrafinil or lactose, the placebo control. Adrafinil caused an increase in locomotor activity at the three highest doses at both the 2- and 10-h intervals and during both the first (days 1 and 5) and second treatment week (days 9 and 13). Adrafinil also caused a transient increase in directed sniffing. At the highest dose level, adrafinil caused a decrease in urination frequency. The increased locomotion was generally unaccompanied by stereotypical behavior in the test session. There was some variability; a subpopulation of animals showed either no effect, or decreased locomotion. The individual differences were correlated with changes in serum levels of adrafinil 10 h following treatment.

Adrafinil: structure
Adrafinil and the mouse
Adrafinil and the monkey
Adrafinil and aged beagles
Smart drugs for dumb dogs?

BLTC Research
Utopian Pharmacology
The Hedonistic Imperative

swan image
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family